AI Article Synopsis
- The effectiveness of buprenorphine for treating opiate dependence has been established since before its federal approval in October 2002.
- The article emphasizes the need for practical, clinical experience from healthcare providers in managing buprenorphine treatment.
- It shares insights from patient anecdotes and outlines important considerations for treatment providers looking to incorporate care for opiate-addicted individuals into their practice.
Article Abstract
The viability of using buprenorphine to treat opiate dependence was well documented prior to federal approval in October 2002. What has been lacking in the literature is "hands-on" experience of providers from a clinical management and practice management perspective. This article adds to the knowledge base by providing information about buprenorphine treatment as well as anecdotes from patients treated by the authors, leading to a detailed list of factors worth considering for the treatment provider contemplating adding an opiate-addicted population to an existing treatment base.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1300/J069v26n01_02 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Buprenorphine: An anesthesia-centric review.
J Opioid Manag
January 2024
Harvard Medical School; MGH/Harvard Center for Addiction Medicine, Massachusetts General Hospital; Addiction Leadership, Charlestown Community Health Care Center for Pain Management; HOME BASE Veterans and Family Care, Boston, Massachusetts.
Buprenorphine was synthesized in the 1960s as a result of a search for a safe and effective opioid analgesic. Present formulations of buprenorphine are approved for the treatment of both acute and chronic pain. Its long duration of action, high affinity, and partial agonism at the µ-opioid receptor have established it as a mainstay treatment for opioid use disorder (OUD).
View Article and Find Full Text PDFPharmacological Strategies to Decrease Long-Term Prescription Opioid Use: A Systematic Review.
J Clin Med
December 2024
Department of Pharmacy, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
: As long-term prescription opioid use is associated with increased morbidity and mortality, timely dose reduction of prescription opioids should be considered. However, most research has been conducted on patients using heroin. Given the differences between prescription and illicit opioid use, the aim of this review was to provide an overview of pharmacological strategies to reduce prescription opioid use or improve clinical outcomes for people who experience long-term prescription opioid use, including those with opioid use disorder.
View Article and Find Full Text PDFBuprenorphine and postpartum contraception utilization among people with opioid use disorder: a multi-state analysis.
Addict Sci Clin Pract
January 2025
Departments of Family and Community Medicine and Health and Clinical Outcomes Research, Saint Louis University School of Medicine, Saint Louis, MO, USA.
Background: The postpartum period provides an opportunity for birthing people with opioid use disorder (OUD) to consider their future reproductive health goals. However, the relationship between the use of medication for opioid use disorder (MOUD) and contraception utilization is not well understood. We used multistate administrative claims data to compare contraception utilization rates among postpartum people with OUD initiating buprenorphine (BUP) versus no medication (psychosocial services receipt without MOUD (PSY)) in the United States (US).
View Article and Find Full Text PDFTreatment of Inpatient Opioid Withdrawal with Short-Acting Full Agonist Opioids at a Safety-Net Hospital.
J Gen Intern Med
January 2025
University of California, San Francisco, 1001 Potrero Avenue, Bldg 5 Rm 5H06, San Francisco, CA, 94110, USA.
Background: Fentanyl use leads to increased opioid tolerance in people with opioid use disorder, complicating management of opioid withdrawal syndrome. While accepted as gold standard, methadone and buprenorphine may be insufficient to treat acute opioid withdrawal. Short-acting full agonist opioids (SAFAO) may improve treatment in the acute care setting.
View Article and Find Full Text PDFEffect of buprenorphine delivered by target-controlled infusion on the minimum alveolar concentration of isoflurane in cats.
Vet Anaesth Analg
January 2025
Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, CA, USA.
Objective: To characterize the effect of buprenorphine on the minimum alveolar concentration of isoflurane (MACiso) in cats.
Study Design: Randomized, crossover, experimental study.
Animals: A group of six healthy male neutered cats, aged 2-8 years with body mass 5.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!